Factors associated with use of bone morphogenetic protein during pediatric spinal fusion surgery: An analysis of 4817 patients

Journal of Bone and Joint Surgery

Volumn 95, Issue 14, 2013, Pages 1265-1270

  Jain, Amit ^a   Kebaish, Khaled M ^a   Sponseller, Paul D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN;

ADOLESCENT; ADOLESCENT IDIOPATHIC SCOLIOSIS; AGE DISTRIBUTION; ANTERIOR SPINE FUSION; ARTICLE; BONE GRAFT; DRUG USE; HOSPITAL BED CAPACITY; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; PEDIATRIC SURGERY; POSTERIOR SPINE FUSION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; REFERENCE DATABASE; SCHEUERMANN DISEASE; SCOLIOSIS; SPINE FRACTURE; SPONDYLOLISTHESIS; TEACHING HOSPITAL; AGE; BONE TRANSPLANTATION; CHILD; CLINICAL PRACTICE; FEMALE; HEALTH CARE SURVEY; LUMBAR VERTEBRA; MALE; METHODOLOGY; SPINE DISEASE; SPINE FUSION; VERTEBRA;

ADOLESCENT; AGE FACTORS; BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; CHILD; FEMALE; HEALTH CARE SURVEYS; HUMANS; LUMBAR VERTEBRAE; MALE; PHYSICIAN'S PRACTICE PATTERNS; SPINAL DISEASES; SPINAL FUSION; THORACIC VERTEBRAE;

EID: 84884477539     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.01118     Document Type: Article

References (32)

1. Boakye M, Mummaneni PV, Garrett M, Rodts G, Haid R. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine. 2005 May;2(5):521-5.
2. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am. 2005 Jun;87(6):1205-12.
3. Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am. 2009 Jun;91(6):1377-86.
4. Glassman SD, Carreon LY, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar Jr. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976). 2008 Dec 15;33(26):2843-9.
5. Haid RW Jr, Branch CL Jr, Alexander JT, Burkus JK. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004 Sep-Oct;4(5):527-38; discussion 538-9.
6. Villavicencio AT, Burneikiene S, Nelson EL, Bulsara KR, Favors M, Thramann J. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine. 2005 Dec;3(6):436-43.
7. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976). 2006 Oct 15;31(22):2534-9; discussion 2540.
8. Vaccaro AR, Whang PG, Patel T, Phillips FM, Anderson DG, Albert TJ, Hilibrand AS, Brower RS, Kurd MF, Appannagari A, Patel M, Fischgrund JS. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum4-year follow-up of a pilot study. Spine J. 2008 May-Jun;8(3):457-65.
9. Goulet JA, Senunas LE, DeSilva GL, Greenfield MLVH. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res. 1997 Jun;(339):76-81.
10. Pollock R, Alcelik I, Bhatia C, Chuter G, Lingutla K, Budithi C, Krishna M. Donor site morbidity following iliac crest bone harvesting for cervical fusion: a comparison between minimally invasive and open techniques. Eur Spine J. 2008 Jun;17(6):845-52.
11. U. S. Food and Drug Administration. InFUSETM Bone Graft/LT-CAGETM Lumbar Tapered Fusion Device - P000058. http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm083423.htm. Accessed 2012 Jun 22.
12. U. S. Food and Drug Administration. OP-1 Putty - H020008. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/ deviceapprovalsandclearances/recently-approveddevices/ucm081181.htm. Accessed 2012 Jun 22.
13. U. S. Food and Drug Administration. INFUSE/MASTERGRAFTTM posterolateral revision device. http://www.accessdata.fda.gov/cdrh-docs/pdf4/H040004c.pdf. Accessed 2012 Jun 22.
14. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009 Jul 1;302(1):58-66.
15. Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976). 2010 Sep 1;35(19):1794-800.
16. Abd-El-Barr MM, Cox JB, Antonucci MU, Bennett J, Murad GJA, Pincus DW. Recombinant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population. Pediatr Neurosurg. 2011;47(4):266-71.
17. Betz RR, Lavelle WF, Samdani AF. Bone grafting options in children. Spine (Phila Pa 1976). 2010 Aug 1;35(17):1648-54.
18. Fahim DK, Whitehead WE, Curry DJ, Dauser RC, Luerssen TG, Jea A. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine: safety profile and efficacy in the early postoperative period. Neurosurgery. 2010 Nov;67(5):1195-204; discussion 1204.
19. Lindley TE, Dahdaleh NS, Menezes AH, Abode-Iyamah KO. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis. J Neurosurg Pediatr. 2011 May;7(5):468-74.
20. Oluigbo CO, Solanki GA. Use of recombinant human bone morphogenetic protein-2 to enhance posterior cervical spine fusion at 2 years of age: technical note. Pediatr Neurosurg. 2008;44(5):393-6.
21. Dodwell E, Snyder B, Wright J. Off-label use of bone morphogenetic proteins in pediatric spinal arthrodesis. JAMA. 2012 Oct 10;308(14):1429-32.
22. Woo EJ. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database. Spine J. 2012 Oct;12(10):894-9.
23. National Center for Health Statistics, Centers for Medicare and Medicaid Services. ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification. Washington, DC: Department of Health and Human Services; 2010.
24. Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976). 2011 Feb 15;36(4): E274-81.
25. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716-23.
26. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery. 2008 May;62(5)(Suppl 2):ONS423-31; discussion ONS431.
27. Polly DW Jr, Ackerman SJ, Shaffrey CI, Ogilvie JW, Wang JC, Stralka SW, Mafilios MS, Heim SE, Sandhu HS. A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. Orthopedics. 2003 Oct;26(10):1027-37.
28. Mulconrey DS, Keeler KA, Lenke LG, Bridwell KH, Good CR, O'Leary PT, Pichelmann M, Sides BA. Safety and efficacy of bone morphogenetic protein (rhBMP-2) in a complex pediatric spinal deformity at a minimum 2-year follow-up. Read at the 15th International Meeting on Advanced Spine Techniques; 2008 Jul 8-11; Hong Kong, China.
29. Oetgen ME, Richards BS. Complications associated with the use of bone morphogenetic protein in pediatric patients. J Pediatr Orthop. 2010 Mar;30(2): 192-8.
30. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011 Jun;11(6):471-91.
31. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976). 2002 Dec 1;27(23):2662-73.
32. The United States Committee on Finance. Baucus, Grassley question Medtronic about unreported side effects, financial ties to clinical investigators. http://www.finance.senate.gov/newsroom/chairman/release/?id= a7e974b6-b4b6-4e2c-a738-edefac30fcb6. Accessed 2012 Nov 18.